PMID- 11524240
OWN - NLM
STAT- MEDLINE
DCOM- 20011004
LR  - 20190709
IS  - 0022-0795 (Print)
IS  - 0022-0795 (Linking)
VI  - 170
IP  - 3
DP  - 2001 Sep
TI  - Androgen responsiveness of the pituitary gonadotrope cell line LbetaT2.
PG  - 601-7
AB  - Androgens have a profound effect on the hypothalamic-pituitary axis by reducing 
      the synthesis and release of the pituitary gonadotropin LH. The effect on LH is 
      partly a consequence of a direct, steroid-dependent action on pituitary function. 
      Although androgen action has been well studied in vivo, in vitro cell models of 
      androgen action on pituitary gonadotropes have been scarce. Recently, an 
      LH-expressing cell line, LbetaT2, was generated by tumorigenesis targeted to the 
      LH-producing cells of the mouse pituitary. The purpose of these studies was to 
      determine the presence of androgen receptor (AR) and establish its function in 
      this cell line. RT-PCR analysis indicated that the LbetaT2 cell line expresses AR 
      mRNA. Transient transfection assays, using the mouse mammary tumor virus (MMTV) 
      promoter, showed that a functional AR is also present. Testosterone (TEST), 
      dihydrotestosterone (DHT), 7alpha-methyl-19-nortestosterone (MENT), and 
      fluoxymesterone (FLUOXY) increased reporter gene activity in the rank order of 
      potencies MENT>DHT> TEST>FLUOXY. Additionally, activation of MMTV promoter 
      activity by DHT in LbetaT2 cells was diminished by the AR antagonists casodex and 
      2-hydroxy-flutamide, indicating that the effects of DHT are mediated through AR. 
      In summary, these studies showed that the LbetaT2 cell line is a useful model for 
      the evaluation and molecular characterization of androgen action in pituitary 
      gonadotropes.
FAU - Lawson, M A
AU  - Lawson MA
AD  - Department of Pharmacology, Ligand Pharmaceuticals Inc., 10275 Science Center 
      Drive, San Diego, California 92121, USA.
FAU - Li, D
AU  - Li D
FAU - Glidewell-Kenney, C A
AU  - Glidewell-Kenney CA
FAU - Lopez, F J
AU  - Lopez FJ
LA  - eng
GR  - R01HD-37568/HD/NICHD NIH HHS/United States
GR  - U54HD-12303/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Androgens)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Androgen)
RN  - 08J2K08A3Y (Dihydrotestosterone)
RN  - 9002-67-9 (Luteinizing Hormone)
SB  - IM
MH  - Androgen Receptor Antagonists
MH  - Androgens/*pharmacology
MH  - Animals
MH  - Dihydrotestosterone/pharmacology
MH  - Gene Expression
MH  - Genes, Reporter
MH  - Luteinizing Hormone/biosynthesis
MH  - Mice
MH  - Pituitary Gland, Anterior/cytology/*drug effects/metabolism
MH  - RNA, Messenger/genetics
MH  - Receptors, Androgen/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Cells, Cultured
EDAT- 2001/08/29 10:00
MHDA- 2001/10/05 10:01
CRDT- 2001/08/29 10:00
PHST- 2001/08/29 10:00 [pubmed]
PHST- 2001/10/05 10:01 [medline]
PHST- 2001/08/29 10:00 [entrez]
AID - JOE04325 [pii]
AID - 10.1677/joe.0.1700601 [doi]
PST - ppublish
SO  - J Endocrinol. 2001 Sep;170(3):601-7. doi: 10.1677/joe.0.1700601.